Company: BIAF
Filing Date: 2025-04-22
Form Type: 424B3
Source: 0001641172-25-005598
Chunk: 178

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-04-22
Form: 424B3
Chunk 178
---
.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

/s/ WithumSmith+Brown, PC

We have served as the Company’s auditor since 2021.

New York, New York

March 31, 2025

PCAOB ID Number 100

| F-2 |

<div align='center'>bioAffinity Technologies, Inc.

Consolidated Balance Sheets

as of December 31, 2024 and 2023</div>

| ASSETS                                                                                                                              
 Current assets:                                                                                                                     |     | December 
 31,      
 2024     |             |   |     | 2023 |             |   |
|:------------------------------------------------------------------------------------------------------------------------------------|:----|:---------|------------:|:--|:----|:-----|------------:|:--|
| Cash and                                                                                                                            
 cash equivalents                                                                                                                    |     | $        |   1,105,291 |   |     | $    |   2,821,570 |   |
| Accounts and other receivables,                                                                                                     
 net                                                                                                                                 |     |          |   1,139,204 |   |     |      |     811,674 |   |
| Inventory                                                                                                                           |     |          |      27,608 |   |     |      |      18,484 |   |
| Prepaid